ELOX — Eloxx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1035354 ·
Last close
$15.03
Market Cap
$51.65M
52W High
$23.40
52W Low
$8.20
ADV30
39,053
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,450,000 | -4,502,000 | 63,388,000 | 61,960,000 | 16,968,000 |
| Mar 2026 | 0 | — | -3,795,000 | -3,754,000 | 8,503,000 | 6,363,000 | 16,087,000 |
| Jun 2025 | 0 | — | -1,582,000 | -1,891,000 | — | — | — |
| Mar 2025 | 0 | — | -1,222,000 | -1,709,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,249,000
Investing CF
—
Financing CF
$6,166,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.83
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-304,334,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-4,951,000
Pretax Income TTM
$-5,463,000
Interest Exp TTM
$512,000
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,438,000 | -5,995,000 | 5,270,000 | 17,177,000 | -11,907,000 | -6,327,000 |
| Dec 2024 | 6,359,000 | -2,468,000 | -3,143,000 | 2,976,000 | 27,311,000 | -24,335,000 | -4,715,000 |
| Dec 2023 | 0 | -17,288,000 | -17,054,000 | 1,712,000 | 24,311,000 | -22,599,000 | -14,341,000 |
| Dec 2022 | 0 | -34,419,000 | -36,065,000 | 21,123,000 | 31,783,000 | -10,660,000 | -31,845,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.71
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BKHA | Black Hawk Acquisition Corp | $50.96M | $12.27 | — |
| IMA | ImageneBio, Inc. | $53.69M | $4.72 | — |
| TIL | Instil Bio, Inc. | $48.63M | $7.17 | — |
| INMB | Inmune Bio, Inc. | $56.34M | $2.03 | — |
| TVGN | Tevogen Inc. | $47.21M | $7.25 | — |
News headlines (Yahoo Finance, 1h cache)
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
2026-09-11 11:30 · Yahoo
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-12 10:00 · Yahoo
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
2026-06-09 01:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.